SEC Filing Summary
Filing identity: The provided filing is Health Sciences Acquisitions Corporation’s Form 10-Q for the quarter ended September 30, 2019, filed November 13, 2019. It is not an Immunovant, Inc. filing and does not cover “2019 Q2”; the source text reflects a special purpose acquisition company before its proposed combination with Immunovant.
Business Context and Reporting Period
Health Sciences Acquisitions Corporation was a Delaware blank-check company formed on December 6, 2018, to pursue a business combination, with an intended focus on healthcare, biopharmaceutical and medical technology businesses in North America or Europe. It had not commenced operating activities or generated operating revenue as of September 30, 2019.
On September 29, 2019, the company entered into a share exchange agreement with Immunovant Sciences Ltd. Under the proposed transaction, Immunovant would become a wholly owned subsidiary and the combined company would be renamed Immunovant, Inc.
Financial Condition and Performance
| Metric | Three Months Ended September 30, 2019 | Nine Months Ended September 30, 2019 |
|---|---|---|
| Operating costs and franchise taxes | $419,757 | $512,549 |
| Interest income | $683,140 | $1,024,698 |
| Income tax expense | $138,293 | $204,760 |
| Net income | $125,090 | $307,389 |
| Net income per redeemable share | $0.05 | $0.07 |
| Net loss per non-redeemable share | $(0.14) | $(0.16) |
- Revenue and margins: No operating revenue was generated. Results consisted primarily of interest income from the Trust Account less organizational, public-company and transaction-related costs and taxes; conventional operating margins are therefore not meaningful.
- Cash flow: Net cash used in operating activities was $532,235 for the nine months. Investing activities used $115.0 million to fund the Trust Account, while financing activities provided $116.8 million. Ending cash outside the Trust Account was $1.61 million.
- Liquidity: Total assets were $117.8 million, including $116.0 million in cash and marketable securities held in the Trust Account and $1.61 million of unrestricted cash. The Trust Account consisted primarily of U.S. Treasury bills.
- Debt and obligations: Total liabilities were $4.36 million, including a $4.025 million deferred underwriting fee payable upon completion of a business combination. The company reported no long-term debt, capital leases or operating leases. Related-party advances and a $300,000 promissory note were repaid in May 2019.
- Capitalization: Common stock subject to possible redemption was recorded as temporary equity at $108.4 million. Stockholders’ equity was $5.0 million.
Material Changes Versus the Prior Comparable Period
- The company completed its initial public offering on May 14, 2019, selling 11.5 million units for gross proceeds of $115.0 million, including the full underwriters’ over-allotment exercise.
- The sponsor purchased 10.0 million private warrants for $5.0 million.
- Cash and marketable securities increased from $325,000 at December 31, 2018 to $117.6 million at September 30, 2019, primarily due to the IPO and Trust Account funding.
- Total assets increased from $405,000 to $117.8 million, while total liabilities increased from $380,448 to $4.36 million, principally because of the deferred underwriting fee.
- Retained earnings improved from a $448 accumulated deficit at December 31, 2018 to $306,941 of retained earnings at September 30, 2019.
- The filing provides no prior-year quarterly income statement comparison; the company was formed in December 2018 and had no comparable operating period.
Guidance, Outlook, Risks and Unusual Items
- Management expected no operating revenue until completion of a business combination and anticipated continued legal, accounting, due diligence and public-company compliance costs.
- The proposed Immunovant transaction contemplated issuing approximately 43 million common shares, or reserving shares for currently exercisable options, and 10,000 shares of Series A preferred stock to Roivant, subject to specified adjustments. This would substantially dilute existing public stockholders.
- The company was required to complete a business combination by May 14, 2021. If unsuccessful, it would liquidate and redeem 100% of the public shares from the Trust Account, subject to applicable law; the warrants could expire worthless.
- Public stockholders received redemption rights in connection with a business combination. The company must have at least $5,000,001 of net tangible assets after the transaction and generally must acquire a target with a fair market value of at least 80% of Trust Account assets.
- The Trust Account was intended primarily for the business combination. Interest could be used for taxes, while unrestricted cash was intended to fund search, diligence and transaction expenses.
- Management stated that it expected existing unrestricted cash to cover anticipated operating needs, but warned that additional financing might be required for transaction costs, significant shareholder redemptions or post-combination operations.
- The filing disclosed no legal proceedings, no material changes to previously disclosed risk factors, no off-balance-sheet arrangements and no identified material subsequent events.
- Management concluded that disclosure controls and procedures were effective as of September 30, 2019, with no material change in internal control over financial reporting during the quarter.
Facts Investors Should Verify
- Confirm that the relevant filing is for Health Sciences Acquisitions Corporation, not Immunovant, Inc., and that the period ended September 30, 2019 rather than June 30, 2019.
- Verify the closing status and final terms of the September 29, 2019 Immunovant share exchange agreement, including issuance of approximately 43 million common shares and Series A preferred stock.
- Review the Trust Account balance, deferred underwriting fee, redemption provisions and the May 14, 2021 business-combination deadline.
- Assess dilution from founder shares, public and private warrants, proposed transaction shares and converted options.
- Review Immunovant’s separate financial statements, clinical-development requirements, financing needs and operating risks, which are not presented in this SPAC filing.